Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H E Bays

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Postgraduate Medicine|June 1, 1992
Clarification. Drug therapy for hyperlipidemia: when reducing cardiovascular risk is a priorityH E Bays
Drug Safety|November 24, 1998
Drug interactions of lipid-altering drugsH E Bays, C A Dujovne
Progress in Drug Research. Fortschritte Der Arzneimittelforschung. Progres Des Recherches Pharmaceutiques|January 1, 1994
Drugs for treatment of patients with high cholesterol blood levels and other dyslipidemiasH E Bays, C A Dujovne
The Medical Clinics of North America|November 1, 1988
Peripheral diabetic neuropathyH E Bays, M A Pfeifer
Drugs of Today (Barcelona, Spain : 1998)|February 22, 2012
Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesityH E Bays, K M Gadde
Drugs in R&D|November 24, 1999
Lipid-altering drugs in developmentH E Bays, C A Dujovne
Postgraduate Medicine|April 1, 1992
Drug therapy for hyperlipidemia. When reducing cardiovascular risk is a priorityH E Bays, C A Dujovne
International Journal of Clinical Practice|December 5, 2008
Does nicotinic acid (niacin) lower blood pressure?H E Bays, D J Rader
International Journal of Clinical Practice|May 12, 2007
The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveysH E Bays, R H Chapman, S Grandy, et al.
International Journal of Clinical Practice|July 13, 2010
The Bile Acid Sequestrant Acceptability scale validation studyH E Bays, K C Maki, K Schmitz
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Postgraduate Medicine|June 1, 1992
Clarification. Drug therapy for hyperlipidemia: when reducing cardiovascular risk is a priorityH E Bays
Drug Safety|November 24, 1998
Drug interactions of lipid-altering drugsH E Bays, C A Dujovne
Progress in Drug Research. Fortschritte Der Arzneimittelforschung. Progres Des Recherches Pharmaceutiques|January 1, 1994
Drugs for treatment of patients with high cholesterol blood levels and other dyslipidemiasH E Bays, C A Dujovne
The Medical Clinics of North America|November 1, 1988
Peripheral diabetic neuropathyH E Bays, M A Pfeifer
Drugs of Today (Barcelona, Spain : 1998)|February 22, 2012
Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesityH E Bays, K M Gadde
Drugs in R&D|November 24, 1999
Lipid-altering drugs in developmentH E Bays, C A Dujovne
Postgraduate Medicine|April 1, 1992
Drug therapy for hyperlipidemia. When reducing cardiovascular risk is a priorityH E Bays, C A Dujovne
International Journal of Clinical Practice|December 5, 2008
Does nicotinic acid (niacin) lower blood pressure?H E Bays, D J Rader
International Journal of Clinical Practice|May 12, 2007
The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveysH E Bays, R H Chapman, S Grandy, et al.
International Journal of Clinical Practice|July 13, 2010
The Bile Acid Sequestrant Acceptability scale validation studyH E Bays, K C Maki, K Schmitz
Pageof 2